| 游以勒,王胜锋.磷酸二酯酶5抑制剂与肿瘤发病关联研究的新进展[J].中华流行病学杂志,2023,44(9):1486-1490 |
| 磷酸二酯酶5抑制剂与肿瘤发病关联研究的新进展 |
| Progress in research of association between phosphodiesterase 5 inhibitors and cancer incidence |
| 收稿日期:2023-02-13 出版日期:2023-09-14 |
| DOI：10.3760/cma.j.cn112338-20230213-00072 |
| 中文关键词: 磷酸二酯酶5抑制剂 肿瘤 发病风险 关联研究 机制 |
| 英文关键词: Phosphodiesterase 5 inhibitors Cancer Incidence risk Association study Mechanism |
| 基金项目:国家重点研发计划（2022YFC3602900）；国家自然科学基金（82173616） |
|
| 摘要点击次数: 2520 |
| 全文下载次数: 829 |
| 中文摘要: |
| 伴随磷酸二酯酶5抑制剂（PDE5Is）用药数量的逐年增加，大量人群研究提示PDE5Is与特定肿瘤发病风险存在潜在关联。本文针对PDE5Is与各种肿瘤发病风险关联及机制研究进行系统梳理，已有研究进行Meta分析，结果显示，使用PDE5Is可能与黑色素瘤（RR=1.11，95%CI：1.02~1.22）、基底细胞癌（RR=1.16，95%CI：1.13~1.20）发病风险增加相关，鳞状细胞癌结果尚不一致，与前列腺癌（OR=0.71，95%CI：0.40~1.29）无统计学关联，对结直肠癌（RR=0.85，95%CI：0.76~0.95）可能具有预防作用。建议未来针对现有研究的经验及不足开展进一步深入探索。 |
| 英文摘要: |
| With the increased use of phosphodiesterase 5 inhibitors (PDE5Is) over the past years, several population based studies have suggested a potential association between PDE5Is and the risk for specific cancers. This paper systematically summarizes the current status of relatedstudies. Meta-analyses on current research indicated that the use of PDE5Is might be associated with the increased risk for melanoma (RR=1.11, 95%CI:1.02-1.22) and basal cell carcinoma (RR=1.16, 95%CI:1.13-1.20), but not for prostate cancer (OR=0.71, 95%CI:0.40-1.29), and might have chemoprophylaxis effect on colorectal cancer (RR=0.85, 95%CI:0.76-0.95). However, results of squamous cell carcinoma were still inconsistent. Further exploration based on the experience and limitations of current research is suggested. |
|
查看全文
Html全文
查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
